Immuron submits Coffee Microcaps Conference presentation
IMRN•Conference presentation and pipeline overview
Immuron published an investor presentation tied to CEO Steven Lydeamore’s Coffee Microcaps Conference slot on Sept. 22, 2026.
The slides outline Travelan, an oral passive immunotherapy positioned to reduce the risk of travelers’ diarrhea caused by pathogenic bacteria.
The pipeline summary highlights IMM-529 for recurrent C. difficile infection as an adjunct to antibiotics, targeting toxin B, spores, and surface proteins.
The presentation also covers ProIBS distribution in Australia and New Zealand, describing it as a medical device for IBS symptoms.
Links cited: https://www.immuron.com.au/ | https://www.travelan.com
Related News
U.S. FDA Approves Update To The Label For Winrevair To Include Data From The Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed With Pulmonary Arterial Hypertension
MRK•
Lithia & Driveway: Citigroup Cuts Target Price to $409 From $455
LAD•
